J. Hjelmgren

发表

Health economic modeling of the potential cost saving effects of Neurally Adjusted Ventilator Assist

J. Hjelmgren, S. Bruce Wirta, P. Huetson, 2016, Therapeutic advances in respiratory disease.

Implementing competition in the pharmacy sector: lessons from Iceland and Norway.

A. Anell, J. Hjelmgren, 2002, Applied health economics and health policy.

Original Research Articles – Clinical Science: Annual costs of treatment for venous leg ulcers in Sweden and the United Kingdom

G. Ragnarson Tennvall, J. Hjelmgren, 2005, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden

T. Wisløff, U. Persson, A. Bergman, 2008, Scandinavian journal of infectious diseases.

The Potential Cost and Cost-Effectiveness Impact of Using a Machine Learning Algorithm for Early Detection of Sepsis in Intensive Care Units in Sweden

I. Persson, F. Sjövall, J. Hjelmgren, 2022, Journal of health economics and outcomes research.

A Cohort Study Based on Patients' Records from Four Hospitals in Sweden

U. Persson, J. Hjelmgren, J. Ceberg, 2003 .

The Cost of Treating Pancreatic Cancer

U. Persson, T. Alvegård, J. Hjelmgren, 2003, Acta oncologica.

[Health services need knowledge of how the public values health].

U. Persson, J. Hjelmgren, 2003, Lakartidningen.

JAK2 V617F as a Marker for Long-Term Disease Progression and Mortality in Polycythemia Vera and its Role in Economic Modeling

G. Birgegard, J. Hjelmgren, K. Nilsson, 2020, Journal of health economics and outcomes research.

Health economic guidelines--similarities, differences and some implications.

J Hjelmgren, F Berggren, F Andersson, 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.

B. Barber, C. Graham, G. Hechmati, 2014, European journal of cancer.

Patient preferences and willingness-to-pay for ADHD treatment with stimulants using discrete choice experiment (DCE) in Sweden, Denmark and Norway

A. Glenngård, J. Hjelmgren, P. Thomsen, 2013, Nordic journal of psychiatry.

Population preferences and choice of primary care models: a discrete choice experiment in Sweden.

A. Anell, J. Hjelmgren, 2007, Health policy.

[Treatment of venous leg ulcers is costly for the health care and the society. The value of preventive measures should be further investigated according to a study].

G. Ragnarson Tennvall, J. Hjelmgren, 2005, Läkartidningen.

Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, Lopinavir-Naive, Protease Inhibitor-Resistant, HIV-Infected Adults in Belgium, Italy, Sweden and the UK

K. Moeremans, J. Hjelmgren, E. Smets, 2012, PharmacoEconomics.

Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

M. Fakih, B. Barber, C. Graham, 2015, Journal of medical economics.

Differences in health care utilisation and workdays lost between individuals with and without asthma.

B. Lindgren, J. Hjelmgren, F. Berggren, 2003, Applied health economics and health policy.

Estimating the value of novel interventions for Parkinson's disease: an early decision-making model with application to dopamine cell replacement.

O. Lindvall, U. Persson, P. Hagell, 2006, Parkinsonism & related disorders.

Cost-Effectiveness of Vaccination of Older Adults with an MF59®-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden

T. Biering-Sørensen, Emanuele Ciglia, J. Mould-Quevedo, 2023, Vaccines.

Are treatment satisfaction, quality of life, and self-assessed disease severity relevant parameters for patient registries? Experiences from Finnish and Swedish patients with psoriasis.

Å. Svensson, A. Bergman, J. Hjelmgren, 2011, Acta dermato-venereologica.

Under what conditions is feedback microwave thermotherapy (ProstaLund Feedback Treatment) cost-effective in comparison with alpha-blockade in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms?

G. Ragnarson Tennvall, J. Hjelmgren, L. Malmberg, 2006, Scandinavian journal of urology and nephrology.

[Treatment of venous leg ulcers can be better and cheaper. Annual costs calculation based on an inquiry study].

M. Bjellerup, J. Hjelmgren, G. R. Tennvall, 2004, Lakartidningen.

Cost‐effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health‐economic model simulation based on a patient survey and clinical trial data

Å. Svensson, G. Ragnarson Tennvall, J. Hjelmgren, 2007, The British journal of dermatology.

Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.

M. Fakih, T. Price, B. Barber, 2016, Clinical therapeutics.

Cost-effectiveness analysis of panitumumab plus mFOLFOX 6 compared with bevacizumab plus mFOLFOX 6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

B. Barber, C. Graham, G. Hechmati, 2014 .

Local Treatment Pattern Versus Trial-based Data: A Cost-effectiveness Analysis of Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis in Sweden

U. Persson, J. Hjelmgren, G. R. Tennvall, 2005, American journal of therapeutics.

PHL6 TREATMENT OF LEG ULCERS IN SWEDEN STILL DEMANDS LARGE RESOURCES IN SPITE OF IMPROVED MANAGEMENT—THE COST OF ILLNESS (COI) ESTIMATED FROM A PATIENT SURVEY AND PUBLISHED EPIDEMIOLOGICAL STUDIES

J. Hjelmgren, G. R. Tennvall, 2003 .

PHL7 COST OF TREATMENT (COT) FOR VENOUS LEG ULCERS IN SWEDEN AND THE UK—ESTIMATES FROM CLINICAL EXPERT PANELS AND MODEL SIMULATIONS

J. Hjelmgren, G. R. Tennvall, 2003 .

Cost-Effectiveness Analysis of Panitumumab Plus Mfolfox6 Versus Bevacizumab Plus Mfolfox6 for First-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.

G. de Pouvourville, B. Barber, C. Graham, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.